Cyclotron-based Production of Lanthanum-133 with High Radionuclide Purity for Theranostic Purposes

Objectives:

Targeted Alpha Therapy (TAT) is a research field of highest interest in specialized molecular radionuclide therapy. In particular, the radionuclide actinium-225 provides all necessary physical and chemical properties for a successful clinical application. Although the macropa chelator has shown beneficial properties regarding labelling and stability in vivo as compared with DOTA, the former lacks an imaging radionuclide counterpart to 225Ac. In this connection, lanthanum is an appropriate surrogate for actinium due to its comparable coordination chemistry. Furthermore, the imaging properties of the β+-emitter lanthanum-133 makes it an attractive candidate as a theranostic matched pair to 225Ac. Following our recent publication [1], 133La of high radionuclide purity for theranostic purposes was produced through the 134Ba(p,2n)133La reaction.